A combination kidney and liver dialysis system and method provides a portable, lightweight hemodialysis device that removes uremic toxins, hepatic toxins, water, and impurities from the blood. The method comprises separating the blood into a plasma portion and a cellular portion, immediately returning the cellular portion to the body, providing large volumes of replacement fluids, diluting the plasma portion with replacement fluids, and then manipulating the plasma portion of the blood to pass through hemoperfusion membranes, hemodiafiltration membranes, and extracorporeal membrane oxygenation membranes. Dialysis is performed on the plasma portion of the blood with an albumin dialyzer against an albumin dialysate and a high molecular weight cut off membrane. Dialysis is performed on the plasma portion of blood with a lipid dialysate comprising 10-30% lipid composition, and a high flux dialyzer. The system can also use any form of dialysis technology including hollow fiber, flat plate and microfluidic technology.

A gas/fluid mass exchange apparatus is disclosed. The apparatus comprises a gas permeable membrane which is arranged to separate a first region for receiving a gas flow, from a second region for receiving a fluid flow. The apparatus further comprises support means which is arranged to maintain the shape and orientation of the membrane.

Disclosed is an artificial heart and lung apparatus (100) that can be connected to a patient (P), and transfers removed blood to a human body via a roller pump (120), the system including: the roller pump (120); a blood removal line (101) which transfers removed blood to the roller pump (120); a first blood transfer line (104) that transfers blood, which is transferred from the roller pump (120), to the human body; a blood removal rate sensor (111) that is provided in the blood removal line (101); and a control unit (140), in which the control unit (140) performs control such that a blood transfer rate of the roller pump (120) is in a specific range with respect to a blood removal rate measured by a blood removal rate sensor (111).

The preset invention discloses an artificial heart and lung apparatus (100) including a roller pump (120); a blood removal line (101); a first blood transfer line (104); a blood removal rate sensor (111) and a control unit (140) that performs linked control of the roller pump (120) in correspondence with a blood removal rate. The control unit (140) is capable of detecting that the blood removal rate deviates from a blood removal condition set in advance, and out-of-set condition blood removal is performed.

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets.

Treatment of cardiac tissue via an implantable heart treatment device is described. A device embodiment includes, but is not limited to, a substrate configured for implantation within a body; an electromagnetic signal generator coupled to the substrate and configured to generate one or more electric signals configured to stimulate one or more tissues of a heart within the body; and an energy-carrier molecule delivery device coupled to the substrate and configured to supply one or more non-oxygen cellular energy sources to one or more tissues of the heart within the body.

A variety of medical devices including staples sutures and dental floss with surface treatment on at least one tissue-facing surface to improve biologic function such as to control tissue adhesion are disclosed including heparin surface treatment which provides heparin present in an amount to yield heparin bioactivity of at least one of i) an ATIII binding of at least 2 pmol/cm.sup.2, and ii) a thrombin deactivation of at least 0.2 IU/cm.sup.2; an acrylic surface treatment for coupling thereto of a heparin surface treatment, a collagen surface treatment or both; and an amino-functional polysiloxane surface treatment for coupling thereto of a heparin surface treatment.

A method and system for infusing medical liquid with gasses, the system comprising a gas source, a vacuum pump, a temperature-controlled container including a fluid reservoir coupled to the gas source and the vacuum pump, a heating and cooling system, and a sonicator, and a controller configured to de-gas a liquid in the fluid reservoir by activating the vacuum pump, re-gas the liquid in the fluid reservoir by releasing gas from the gas source to the fluid reservoir via a first fluid line, and deliver the re-gassed liquid from the fluid reservoir to a catheter via a second fluid line.

An artificial lung has a gas exchanger portion with an external circulation-type gas exchanging hollow fiber membrane bundle and a heat exchanger portion with a heat exchanging element. Various design parameters of the gas exchanger and heat exchanger portions are configured to obtain a predetermined performance factor. In one embodiment, the design parameters are adjusted so that when a heat exchange performance coefficient of the artificial lung, a blood filling amount of the artificial lung, and a blood side pressure loss of the artificial lung are measured, they result in a performance factor equal to or greater than 1.5, wherein the performance factor is defined as heat exchange performance coefficient/(blood filling amountblood side pressure loss).

An artificial lung has a gas exchanger portion with an external circulation-type gas exchanging hollow fiber membrane bundle and a heat exchanger portion with a heat exchanging element. Various design parameters of the gas exchanger and heat exchanger portions are configured to obtain a predetermined performance factor. in one embodiment, the design parameters are adjusted so that when a gas exchange performance, a heat exchange performance coefficient, a blood filling amount, and a blood side pressure loss are measured, they result in a performance factor between 1.5 and 2.5, wherein the performance factor is defined as (gas exchange performanceheat exchange performance coefficient)/(blood filling amountblood side pressure loss).